L&l Biopharmaceuticals

Developer of immunotherapies for cancer

placeShanghai, Shanghai, China calendar_todayFounded 2015 language lnlbio.com

Innovation

1 patent family — focus: Chemistry & metallurgy; filing pace dormant. Cited 4 times.

YearFilings
20171

Investor mix

2 investors on record; lead investors include Qiaojing Capital, Panlin Capital.

Investor typeCountShare
Venture capital150%
Private equity150%
Coming soon